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There is inadequate understanding of the epidemiology of Non-Tuberculous Mycobacteria (NTM) among infants in high
tuberculosis burden countries. The objective of this study was to document the incidence and diversity of NTM disease or
colonisation in sputum specimens from infants with presumptive TB, the risk factors, and clinical characteristics, in a high TB
and HIV burden setting in Western Kenya. A cohort of 2900 newborns was followed for 1–2 years to assess TB incidence. TB
investigations included collection of induced sputa and gastric aspirates for culture and speciation by HAIN, Tuberculin Skin
Testing (TST), HIV testing, and chest radiography. The American Thoracic Society Criteria (ATS) were applied to identify NTM
disease. Among 927 (32% of 2900) with presumptive TB, 742 (80%) were investigated. NTM were isolated from 19/742 (2.6%)
infants.M. fortuitumwasmost frequently speciated (32%). Total person-timewas 3330 years. NTM incidencewas 5.7/1,000 person-
years, 95%CI (3.5, 8.7). Infants diagnosed with TB were more likely to haveNTM isolation (odds ratio 11.5; 95%CI 3.25, 41.0). None
of the infants with NTM isolated met the criteria for NTM disease. The incidence of NTM isolation was comparable to similar
studies in Africa. NTM isolation did not meet ATS criteria for disease and could represent colonisation. TB disease appears to be
structural lung disease predisposing to NTM colonisation.
1. Introduction
Non-Tuberculous Mycobacteria (NTM) are environmental
saprophytes widely distributed in water and soil [1]. They are
the genetic progenitors ofM. TuberculosisComplex (MTBC),
after a series of gene deletions and gene acquisitions [2] with
MTBC evolving to a more virulent pathogen. NTM rarely
cause disease except when immune function is impaired [3],
elderly patients and chronic lung disease. However, some
NTM are pathogenic, and recently there has been a reported
increase inNTM lymphadenitis [4, 5] and Buruli ulcers [6, 7].
The shared ancestry of NTMandMTBC is responsible for
immune interference in BCG vaccination, via cross reactive
immune responses [2]. This could be one of the reasons for
low BCG efficacy where NTM are prevalent [2]. Absence
of NTM sensitization was associated with higher efficacy of
BCG against pulmonary and severe forms of tuberculosis
in a systematic review [8]. Surprisingly, the discontinuation
of universal BCG vaccination in these countries has seen
an increase of NTM lymphadenitis in children, suggesting
BCG was also protecting against NTM in that setting [4].
NTM appear to be immune modulators influencing host
interactions in BCG efficacy, TB burden, and NTM disease.
The antigen homologues [2] further decrease accuracy
of biomarkers distinguishing latent TB infection (LTBI) and
NTM exposure.
Pulmonary NTM disease is clinically and radiologically
identical to TB and is so diagnosed, in the absence of
microbiological confirmation in high TB burden settings. It
is a relevant distinction to make as almost all NTM do not
respond to anti-tuberculous therapy [9]. Isolation of NTM in
sputum is not necessarily disease [9]. Data on NTM disease
and prevalent subtypes is limited particularly in countries
with a high TB burden. Most studies report on adults [10–12].
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Few studies on NTM in children have been published on the
continent [13–15]. Most document the proportion of NTM
among those with presumptive TB. There is also a dearth of
knowledge on risk and exposure factors. As infants are the
target age group for TB vaccines in the pipeline, it is useful to
describe the epidemiological landscape of NTM, given their
role in tuberculosis incidence and possibly vaccine efficacy.
The objective of this study was to document the incidence
and diversity of NTM disease or colonisation in sputum
specimens from infants with presumptive TB, the risk factors,
and clinical characteristics, in a high TB and HIV burden
setting.
2. Study Population and Methods
The study took place in Siaya, Western Kenya, a predom-
inantly rural community north of Lake Victoria. The area
has a high prevalence of HIV, TB, and malaria. Most women
delivered at home [21]. The NTM substudy was part of
a prospective cohort study to document the incidence of
TB ahead of TB vaccine trials in the same population.
Presumably, infants are born uninfected; we present the
incidence of NTM in this cohort.
Briefly, parents or guardians of 2900 infants aged zero
to six weeks gave written permission for enrollment of their
newborns between June 2009 and June 2010. Patients were
followed up for at least one year and a maximum of two
years. Through four monthly scheduled visits and ancillary
care visits, infants were identified as having presumptive TB
if they had history of TB contact, symptoms, or signs of
pulmonary TB (failure to thrive, cough or night sweats or
fever for more than two weeks, a history of hospitalization for
HIV/AIDS related illness, lower respiratory tract infections,
meningitis, or TB). Consequently, they were admitted into
a case verification ward for three days. Two fasted sputum
induction specimens and two gastric aspirates were collected
on subsequent mornings. Tuberculin Skin Testing (TST) was
done with two Tuberculin Units (2TU) from Statens Serum
Institut (SSI). TST readings of 10mm and more or 5mm or
more among HIV infected children were considered to be
positive readings. Further, DNA PCR HIV (COBAS HIV-
1 Amplicor by ROCHE) tests and digital chest radiography
were performed.
Patients received anti-tuberculous therapy if they had
microbiological confirmation (definite TB) or clinically,
based on the Keith Edward TB Score (KE Score) Chart of
>7, or <7 if the chest radiograph was suggestive (probable
TB). Mid-Upper Arm Circumference (MUAC) was used
to determine nutritional status for children older than 6
months old at time of TB investigations. Weight for Age Z
Score was used for those less than 6 months. HIV infected
infants were referred for anti-retroviral treatment initiation
and care. Patients vital status at last study contact was
documented.
Chest radiographs were read systematically and classified
as abnormal probable TB, abnormal not TB, or normal [22].
The study was approved by Kenya Medical Research Institute
Independent Ethics Committee (KEMRI-IEC) SSC 1465.The
data used to support the findings of this study are available
from the corresponding author upon request.
We applied the American Thoracic Society’s [23] criteria
to establish clinical significance of positive NTM cultures.
2.1. Laboratory Methods and Sample Decontamination.
Induced sputum and gastric aspirates were transported
to the laboratory at 2 to 8∘C, processed using freshly
prepared N-acetyl L-cysteine (NALC)-4% sodium hydroxide
(NaOH)-2.9% sodium citrate at a final concentration of 1%.
Gastric aspirates with >5ml volume were concentrated by
centrifugation and pellet resuspended with 5ml phosphate
buffer saline (PBS). Digestion was stopped using pH 6.8
PBS after 20 minutes. Centrifugation was done at 3,000
x g for 15 minutes at 4∘c. Supernatant was discarded and
the pellet resuspended with 2ml PBS. This was used for
inoculation of Lowenstein Jensen (LJ) [BD] media (0,2ml),
fluorescent microscopy, and mycobacteria growth indicator
tube (MGIT) [BD] (0.5ml). LJ were incubated in 37∘C
CO
2
incubators for 8 weeks, and MGIT was incubated
in automated BACTEC  MGIT  960 [BD] for 42
days. Artificial sputum was used as a negative control
sample to check for cross-contamination with each batch
processed.
MGIT cultures that turned positive were stained for acid
fast bacilli (AFB) using Ziehl Neelsen (ZN). Contamination
was checked by inoculation and incubation of blood agar
plates at 37∘c and read after 48 hours. Samples that tested
ZN negative but Blood Agar Plate (BAP) positive ≥7 days
later were discarded as contaminated. Those <7 days were
redigested using 4% NaOH as described in MGIT pro-
cedure manual [24]. AFB positive cultures were tested by
immunochromatographic assay (ICA) such as Capilia TB-
Neo (TAUNS Laboratories, Numazu, Japan) or BD MGIT
TBc identification kit ((BD, Franklin Lakes, NJ, USA) to
identify whether NTM or MTBC.
For LJ cultures with visible growth, we assessed colony
morphology. Those suggestive of mycobacteria were identi-
fied using ZN smear, and those AFB positive were tested with
ICA.
NTM culture isolates were genetically identified to the
species level using Genotype Mycobacterium Common
Mycobacterium (CM) or Additional Species (AS) kits (HAIN
Lifescience, Nehren, Germany). The procedure was done
according to manufacturer’s instructions.
2.2. Statistical Methods. Frequency methods were used to
describe the baseline characteristics. Odds ratios were used to
analyze whether differences between those with and without
NTM were due to chance. T-tests were used to compare
the mean age at TB investigations. To evaluate differences
in clinical characteristics, known and potential risk factors,
logistic regression was performed. NTM cases that had
microbiologically confirmed or clinical TB were analysed as
TB cases. A-priori risk factors included infant and maternal
HIV infection, nutritional status, housing, and number of
siblings.
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Figure 1: Study flow chart.
3. Results
Of 2900 infants enrolled, 927 (32%) were suspected to have
TB (presumptive TB) during their 1-2-year follow-up. Of
these 742 (80%) were admitted for investigations (Figure 1).
There were 19 NTM identified following culture (2.6% of
742). Total person-time of follow-up was 3330.3 years. The
incidence of NTM was 5.7 per 1,000 person-years (pyo)
of follow-up (95% CI 3.5, 8.7), while all TB incidence (49
cases) was 15/1000 pyo (95% CI, 11-20) and microbiologically
confirmed TB incidence was 2.7/1,000 pyo. At baseline, there
were no statistically significant differences between those
who had NTM identified versus all other infants (Table 1).
Upon bivariate comparison of clinical characteristics
between presumptive TB patients and NTM cases, there were
no statistically significant differences (Table 2(a)). However,
odds of a positive NTM among infants with TB was eleven-
fold that of infants with no TB (OR 11.6 (95% CI 3.25,
41.0). NTM cases had forty-eight-fold higher odds of having
microbiologically confirmed TB compared to all presumptive
TB (OR 48.3 95% CI 9.3, 249) (Table 2(a)).
There were no differences between NTM cases and other
presumptiveTB cases inmean age at time of TB investigations
(Table 2(b)).
Table 3 shows the NTM identified and the individual’s
clinical characteristics. M. fortuitum (6/19 32%) and M.
scrofulaceum (2/19 11%) were most frequently isolated. Two
of the 19 (11%) were unidentifiable. Two patients had MTBC
and NTM coinfection.
Applying the ATS criteria for diagnosis of NTM disease,
none of the NTM cases qualified as having NTM disease.
Only 1/19 (5.3%) NTM case was HIV infected which had
NTM cultured (M. asiaticum) while 3/19 (16%) were born
to mothers who tested HIV positive but were themselves
uninfected (HUE).
In our study, rapidly growing mycobacteria (RGM),
which form colonies in less than seven days, were isolated
most frequently (10/19) (Table 3). The most frequently iso-
lated NTM in pediatric studies are shown in Table 4. M.
fortuitum was the most frequently isolated NTM among the
identified studies.
4. Discussion
4.1. Burden of NTM. The proportion of NTM in pulmonary
samples of presumptive TB cases in this infant cohort was
relatively low (2.6%; 95% CI 1.5, 3.8). Standard sputum
decontamination procedures were judiciously applied; hence
it is unlikely that NTM yield was affected by this. A similar
study among infants in Uganda and South Africa found 3.7%
[14] and 6% [13], respectively. The epidemiology of exposure
in this region could be nonlinear, where exposure in early
childhood is minimal but increases rapidly in adolescents.
A significantly higher proportion of NTM were identified
among presumptive TB cases in adolescents in the study
area (37.5%), at the time of the study (V. Nduba, Personal
Communication). Nevertheless, the Mozambique cohort and
a survey in Ethiopia had more NTM [15, 20], and the average
prevalence in African adult pulmonary samples was 7.5% in
a systematic review [10]. It is possible that BCG is protective
against NTM colonisation. A twenty-year retrospective study
of NTM notifications in children demonstrated increased
odds of NTM disease when universal BCG vaccination was
halted in Finland [4]. Therefore, BCG could also protect
against colonisation. This can be evaluated conclusively in
head to head comparisons of BCG and recombinant BCG
vaccines presently in phase III clinical trials [25].
4.2. Colonisation or NTM Disease/Clinical Relevance. We
did not find statistically significant differences in baseline
characteristics between NTM cases and other presumptive
TB patients suggesting widespread exposure across the study
population. There were no differences in the clinical or
radiological characteristics between presumptive TB and
NTM cases.
NTM disease is clinically and radiologically indistin-
guishable from TB [9]. Two NTM cases were symptomatic
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Table 1: Baseline characteristics of study sample, infants with presumptive TB and infants with NTM isolated; and comparison between
infants with presumptive TB with and without NTM.
Characteristic Study Sample(n=2900)
Investigated for
Presumptive TB
(n =742)
(N, column %)
NTM positive
(n=19)
(N, row%)
OR (95%CI) ∗
Gender
Female 1412 358 (48%) 10 (2.8%) 1 (ref)
Male 1488 384 (52%) 9 (2.3%) 0.85 (0.35, 2.11)
Enrolment weight
Normal 2674 667 (90%) 16 (2.4%) 1 (ref)
low 226 75 (10%) 3 (4.1%) 2.24 (0.65, 7.73)
Place of birth
Home 1840 510 (69%) 11 (2.2%) 0.77 (0.31, 1.93)
Health facility 1038 229 (31%) 8 (3.5%) 1 (ref)
missing 22 3 (<1%)
Maternal HIV status
HIV negative 2451 598 (81%) 16 (2.7%) 1 (ref)
HIV positive 401 127 (17%) 3 (2.4%) 0.88 (0.25, 3.08)
Unknown 48 17 ( 2%)
Infant HIV status
HIV negative 2827 708 (95%) 18 (2.5%) 1 (ref)
HIV positive 73 34 (5%) 1 (2.9%) 2.17 (0.29, 16.5)
Maternal age category
<19 635 152 (21%) 1 (0.7%) 1 (ref)
20-29 1533 384 (52%) 16 (4.2%) 6.69 (0.89, 50.5)
>29 732 206 (28%) 2 (1.0%) 1.74 (0.16, 19.2)
Maternal Occupation
Unemployed 1676 409 (55%) 11 (2.7%) 1 (ref)
Farmer 864 250 (34%) 5 (2.0%) 0.88 (0.31, 2.54)
Business 260 61 (8%) 2 (3.3%) 1.17 (0.26, 5.32)
Salaried 71 13 (2%) 1 (7.7%) 2.16 (0.28, 17.0)
Unknown 29 9 (1%)
Housing Type
Mud House 1912 523 (71%) 11 (2.1%) 1(ref)
Semi-permanent 527 125 (17%) 4 (3.2%) 1.32 (0.42, 4.17)
Permanent 426 84 (11%) 4 (4.8%) 1.64 (0.52, 5.17)
Other 6 1 (0.1%)
Unknown 29 9 (1.2%)
Number of Siblings
None 649 129 (17%) 3 (2.3%) 1 (ref)
One to three 1497 391 (53%) 14 (3.6%) 2.03 (0.58, 7.10)
>3 754 222 (30%) 2 (0.9%) 0.57 (0.10, 3.44)
Vaccination Status at 6
weeks
Complete 2205 682 (92%) 16(2.4%) 0.48 (0.11, 2.10)
Incomplete 133 29 (4%) 2(7.0%) 1 (ref)
Missing 562 31 (4%) 1(3.2%)
∗Odds of being NTM case among those investigated for presumptive TB, given the category of baseline characteristic.
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Table 2
(a) Comparative clinical characteristics of those investigated for presumptive TB and infants with NTM isolated (categorical).
Clinical Characteristics
Presumptive TB NTM +ve
OR (95%CI)N (column %) N (row%)
(n=742) (n=19)
Any TB case (clinical or conﬁrmed)
No 694 (94%) 16 (2.3%) 1 (ref)
Yes 48 (6.5%) 3 (6.3%) 11.6 (3.25, 41.0)
MTBC +ve TB case
No 733 (99%) 17 (2.3%) 1 (ref)
Yes 9 (1%) 2 (22.2%) 48.3 (9.34, 249)
Chest Radiograph
Normal 590 (80%) 13 (2.2%) 1(ref)
Abnormal not TB 110 (15%) 4 (3.6%) 1.71 (0.55, 5.35)
Abnormal TB 35 (5.0%) 2 (5.7%) 2.80 (0.61, 12.9)
missing 7 (0.9%)
Keith Edward TB score
<7 675 (90%) 17 (2.5%) 1 (ref)
>=7 32 (4.3%) 2 (6.3%) 2.62 (0.58, 11.9)
Missing 35 (4.7%)
Reason for TB suspicion
History of hospitalization
No 283 (38%) 8 (3.4%) 1 (ref)
Yes 426 (57%) 11(2.6%) 0.78 (0.31, 1.97)
Missing 33 (5.0%)
TB Contact History
No 579 (78%) 13(2.3%) 1 (ref)
Yes 131 (18%) 6 (4.6%) 2.57 (0.96, 6.88)
Missing 32 (4.0%)
TST results
Negative 555 (76%) 14 (74%) 1 (ref)
Positive 172 (24%) 5 (26%) 1.15 (0.41, 3.25)
TB symptoms
No 530 (71%) 15 (2.8%) 1 (ref)
Yes 180 (24%) 4 (2.2%) 0.85 (0.28, 2.58)
Missing 32 (4.0%)
Nutritional Status at admission
Healthy 379 (51%) 8 (2.1%) 1 (ref)
At risk 195 (27%) 6 (3.0%) 1.48 (0.51, 4.32)
Moderate Acute 113 (15%) 2 (1.8%) 0.84 (0.18, 4.03)
Malnutrition (MAM)
Severe Acute 40 (5%) 3 (7.5%) 3.73 (0.95, 14.7)
Malnutrition (SAM)
Missing 15 (2%)
(b) Comparative clinical characteristics for those investigated for presumptive TB and infants with NTM isolated (continuous variable).
Clinical Characteristic Categories n Mean age (95% CI) Rank sum p- value/t-test p value
Mean age at TB investigation (months) NTM negative Presumptive TB 718 9.34 (8.95, 9.74) 0.20
NTM case 19 11.0 (8.02, 13.9)
Missing 5
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with a suggestive radiological picture and would have quali-
fied as NTM disease, but MTBC was also isolated from their
sputum. The remainder had no combination of suggestive
clinical or radiological features. We therefore conclude the
NTM cases represent colonization. There is a possibility that
these are laboratory contaminants; however this is unlikely
since we checked for contaminants by having negative con-
trols.
4.3. Risk Factors
4.3.1. Environmental Exposure. We did not identify any envi-
ronmental risk factors for NTM incidence. Unlike MTBC
which is transmitted from person to person, NTM transmis-
sion occurs via repeated environmental exposure. In infants,
this would be through handling by parents and siblings. The
study area is rural. Risk for acquiring NTM is significantly
higher in communities engaged in occupations that generate
aerosols and are exposed to soil for prolonged periods such as
agriculture [26]. It is not clear what the environmental source
of these NTM is.
4.4. Host Factors. Host factors predisposing to NTM isola-
tion were intercurrent MTBC disease and severe undernutri-
tion, although the latter did not reach statistical significance.
Past history of TB has been known to be a risk factor for
NTM disease [27, 28], since we studied infants that could
not be confirmed. Interestingly, in this study, MTBC isolation
increased the odds of NTM isolation almost fifty-fold. NTM-
MTBC coinfection in the same infant host has been observed
[13, 15], and in adults in high TB burden countries [29]. TB
appears to be a preexisting lung condition predisposing to
NTM colonisation [9].
Low Body Mass Index and poor nutrition are other
possible host factors, even predicting risk of disseminated
NTM disease in other studies [30, 31], our study seemed to
show the same trend.
Only in one case was the NTM case HIV infected,
indicating among infants in this region, immunodeficiency
is not a factor in NTM isolation in sputum.
4.5. NTM Isolated. The spectrum of organisms identified in
this NTM study is similar in type and frequency to those
reported in Uganda [14], Ethiopia [20], and Saudi Arabia
[28]. M. fortuitum was most frequently isolated in these
studies. There could be geographic and climatic factors in
the distribution. All the regions have warm climates. Increase
in latitude and polarity has been shown to be associated
with higher isolation rates of more pathogenic, slow growing
mycobacteria [4, 13, 15].
4.6. TB Diagnostics. There was no detectable difference
in TST positivity between NTM cases and other patients
whereas NTM sensitization is known to be responsible for
false positive TST readings. Indeed false positive TSTs due
to NTM are infrequent and mainly relevant in areas with low
TB endemicity [32].
4.7. BCG Eﬃcacy. NTM influence the relative efficacy of
BCG vaccines [33]. The nature and type of NTM isolated in
TB endemic countries are critical to an efficient vaccination
campaign [2]. The relative frequency of isolated species may
correlate with the prevalence of skin sensitivity to their
antigens, as was shown in Malawi [11]. RGMs have been
shown to be protective against leprosy and TB [11].This could
not be confirmed in the current study due to the low numbers
of NTM isolated.
As there was no unvaccinated control group, it is not
possible to assess efficacy of BCG. Thus, it appears that the
risk of exposure to NTM as a covariate of vaccine efficacy, as
has been previously suggested, is quite low in the target age
group.
4.8. Limitations. Our analysis was limited due to the small
proportion of NTM isolated in this age group. Nevertheless,
it forms a baseline assessment for future studies including
future vaccine trials.
Also, not all infants could be tested for NTM; this was not
the primary objective, and it is challenging to obtain samples
from children without presumptive TB. Therefore, the NTM
incidencemay be an underestimate of theNTMburden in the
population.
5. Conclusions
This study has attempted to document the incidence of NTM
among infants thought to have TB. The clinical relevance of
NTM isolated points to colonisation and not disease, as all the
infants fromwhomNTMwere isolated did not meet the ATS
criteria for disease. Our data shows that a patient presenting
with features of TB is less likely to have NTM disease, in
similar settings.
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